Tuesday, June 02, 2015 8:39:54 PM
Marlene Busko
June 01, 2015
AMSTERDAM, THE NETHERLANDS — Triglyceride-rich-lipoprotein (TRL) cholesterol could be "the next target" to lower a person's risk of cardiovascular events, said Dr Kausik Ray (University of London, UK), speaking here at the International Symposium on Atherosclerosis 2015[1].
Their research, based on data from the Treating to New Targets (TNT) trial[2], showed that higher levels of TRL cholesterol (which is calculated by subtracting non-HDL cholesterol from LDL cholesterol) were associated with an increased 5-year risk of a major cardiovascular event—coronary heart disease death, nonfatal MI, resuscitated cardiac arrest, or stroke—independent of LDL cholesterol.
Moreover, the increased risk of a cardiovascular event with higher levels of TRL cholesterol was significantly reduced with intensive 80-mg/day atorvastatin therapy.
Thus, TRL cholesterol "is a great marker of [cardiovascular] risk, [and] we know it's modifiable with higher-intensity statins," Ray summarized. "The fact that we can lower this [marker] and that the percentage lowering predicts outcome suggest it might be a future target beyond LDL cholesterol."
Ray said the marker will need to be validated in other patient populations. In response to a question from session comoderator Dr Eric Sijbrands (Erasmus University Medical Center, Rotterdam, the Netherlands), Ray noted that triglyceride levels failed to predict the risk of future cardiovascular events in the TNT cohort but TRL cholesterol did.
TRL-Cholesterol Quintiles and 5-Year CV Events
Epidemiologic studies have shown that higher lifetime levels of remnant cholesterol, "which is really TRL cholesterol, not just remnant cholesterol," are associated with a higher risk of ischemic heart disease and MI, Ray explained.
The researchers used data from the TNT trial to test three hypotheses. In a statin-treated population, is TRL cholesterol a marker of cardiovascular risk? Second, is the level of risk modifiable with high-dose vs low-dose (standard-dose) statin? Third, does TRL-cholesterol lowering independently predict a reduction in clinical events?
The TNT trial randomized just over 10,000 individuals with coronary heart disease (previous MI, previous or current angina, or previous coronary revascularization procedure) to an open-label run-in with low-dose atorvastatin followed by randomization to either 10-mg/day or 80-mg/day atorvastatin. The current study divided the TNT participants into quintiles of baseline TRL-cholesterol levels: <19 mg/dL, >19 to <24 mg/dL, >24 to <30 mg/dL, >30 to <39.5 mg/dL, and >39.5 mg/dL.
Ray and colleagues found that the run-in, low-dose atorvastatin reduced the median TRL-cholesterol level from 30 mg/dL to 27 mg/dL (P<0.0001). In the participants who were randomized to high-dose statin, median TRL-cholesterol levels were further reduced to 23 mg/dL (P<0.0001) by 3 months, a reduction that was maintained over time.
In participants who were randomized to low-dose atorvastatin, the 5-year risk of a cardiovascular event increased with increasing baseline levels of TRL cholesterol. The risk increased from 9.72% in quintile 1 (lowest TRL cholesterol) to 13.77% in quintile 5 (highest TRL cholesterol). Individuals with the highest TRL-cholesterol levels had a 49% greater risk of cardiovascular events at 5 years compared with those with the lowest levels (hazard ratio 1.49; 95% CI 1.15–1.92).
In patients who were randomized to high-dose atorvastatin, however, the 5-year risk of a cardiovascular event was similar in all quintiles of TRL cholesterol (7.36% to 9.76%).
With high-dose statin vs standard-dose statin, there was a 2% absolute risk reduction in the rate of the primary end point (5-year cardiovascular events) in patients in quintile 3 of TRL cholesterol, but there was a "huge 4% absolute benefit in the top two quintiles" of TRL cholesterol, Ray pointed out.
Five-Year Risk of a Cardiovascular Event (%)
Quintile of baseline TRL-cholesterol (mg/dL) Atorvastatin 80 mg/day Atorvastatin 10 mg/day Absolute relative risk HR (95% CI)
<19 9.76 9.72 +0.04 1.01 (0.77– 1.34)
>19 to <24 8.20 8.62 -0.42 0.98 (0.71–1.34)
>24 to <30 8.21 10.58 -2.38 0.71 (0.53–0.96)
>30 to <39.5 7.36 12.07 -4.71 0.59 (0.44–0.80)
>39.5 9.84 13.77 -3.92 0.69 (0.53–0.90)
In multivariable models, independent of reductions in LDL cholesterol, a reduction in TRL cholesterol of one standard deviation was associated with a lower risk of the primary outcome (HR 0.93, CI 0.864–0.999).
"This is the first demonstration that when you actually alter [TRL cholesterol] with drug therapy and you reduce it by one standard deviation independent of LDL change, there is an independent association with clinical events," Ray said. "This would suggest that future therapies that modify that fraction will independently lower risk."
Recent AMRN News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/01/2024 08:54:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/01/2024 08:54:46 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/31/2024 11:05:34 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 07/31/2024 11:05:26 AM
- Amarin Reports Second Quarter 2024 Financial Results and Provides Business Update • GlobeNewswire Inc. • 07/31/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/29/2024 09:30:08 PM
- Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Portugal • GlobeNewswire Inc. • 07/17/2024 08:15:00 PM
- Amarin to Report Second Quarter 2024 Financial Results and Host Conference Call on July 31, 2024 • GlobeNewswire Inc. • 07/17/2024 12:00:00 PM
- Amarin Partner EddingPharm Receives Regulatory Approval for VASCEPA® (Icosapent Ethyl) in Mainland China for Cardiovascular Risk Reduction (CVRR) • GlobeNewswire Inc. • 07/08/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 11:30:10 AM
- Amarin Board of Directors Announces CEO Transition • GlobeNewswire Inc. • 06/04/2024 11:30:00 AM
- Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Greece and Announces Exclusive Marketing and Commercialization Agreement with Vianex S.A. • GlobeNewswire Inc. • 05/28/2024 12:15:23 PM
- Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference • GlobeNewswire Inc. • 05/06/2024 12:00:00 PM
- Amarin Reports First Quarter 2024 Business Update and Financial Results • GlobeNewswire Inc. • 05/01/2024 11:00:00 AM
- Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event • GlobeNewswire Inc. • 04/24/2024 06:00:01 PM
- Amarin Announces Results of Annual General Meeting of Shareholders • GlobeNewswire Inc. • 04/22/2024 12:00:25 PM
- Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024 • GlobeNewswire Inc. • 04/15/2024 12:00:00 PM
- Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24 • GlobeNewswire Inc. • 04/08/2024 12:00:00 PM
- New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • PR Newswire (Canada) • 04/08/2024 10:30:00 AM
- New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • GlobeNewswire Inc. • 04/06/2024 07:30:00 PM
- Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe • GlobeNewswire Inc. • 04/03/2024 12:00:00 PM
- Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo • GlobeNewswire Inc. • 03/25/2024 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 03/04/2024 10:30:53 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/04/2024 01:00:24 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/29/2024 12:06:26 PM
FEATURED POET and Luxshare Tech Expand Product Offerings for Artificial Intelligence Networks • Aug 1, 2024 9:28 AM
Management Discusses Financial Filings of Global Arena Holding Inc., for 10-K 2023 and 10-Q, 1st Quarter 2024 • GAHC • Aug 1, 2024 9:14 AM
VAYK Announces LOI to Acquire $1 Million Home Service Company to Support Airbnb Business • VAYK • Aug 1, 2024 9:00 AM
Duane Forrester Joins INDEXR as SVP of Search • MONI • Jul 31, 2024 11:46 AM
Lingerie Fighting Championships Help Fulfill Death-Bed Promise With First Major Motion Picture • BOTY • Jul 31, 2024 9:00 AM
Kona Gold Beverage Significantly Reduces Debt from Multiple Holders • KGKG • Jul 31, 2024 9:00 AM